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Background: Acute perioperative pain is seen in more than 80% of patients 
undergoing surgery, with almost 75% of them experiencing moderate, severe, 
or extreme pain; adequate postoperative pain management is not achieved in a 
satisfactory manner. This styudy was desined ana performed to assess the 
molecular mechanisms of acute pain management in order to find novel 
future perspectives. 
Materials and Methods: In this narrative review, molecular mechanisms of 
currently available pain controlling agents were assessed based on 3 steps: 
preoperative, intraoperative and postoperative phases. Drugs used in each 
phase and potential novel agents were assessed separately. 
Results: many currently available clinical agents were discussed and 
meanwhile, other potential drugs that could be among the future choices are 
discussed. 
Conclusion: cellular and molecular medicine could open new windows in 
order to discover novel agents for management of pain; we will have possibly 
many new agents that will be available in future while they will be different 
from currently used clinical pain killers. 
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Introduction 
The international association for the study of 
pain, defines pain as “an unpleasant sensory and 
emotional experience associated with actual or 
potential tissue damage, or described in terms of such 
damage” (1). Acute postoperative pain is seen in more 
than 80% of patients undergoing surgery, with almost 
75% of them experiencing moderate, severe, or 
extreme pain. Based on reports, adequate 
postoperative pain management is achieved in less 
than half of surgery patients (2). Effective pain 
management in surgery patients helps with overall 
recovery, increases patient satisfaction, and ultimately 
reduces health care cost. It can also decrease 
morbidity and improve surgery outcomes (3).  
Although several new approaches have been 
introduced in the past decade as components of a 
multimodal approach to decrease the side effects and 
improve quality of analgesia, there hasn’t been any 
major improvement in this field in the past decade. In 
this article, we reviewed the major mechanisms 
involved in this process and current clinical strategies 
in managing this pain in surgical patients (4). 
Molecular Mechanisms 
Post-operative pain has a biphasic nature, 
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which makes it more difficult to manage. In the first 
phase, great nociceptive input is produced in the 
surgery, where trauma to the tissue results in the 
production of noxious stimuli. The second phase 
starts after surgery, when inflammation present at the 
site, produces more noxious input. These processes 
initiate pain response in two levels. At peripheral 
level, the prolonged presence of noxious stimuli 
results in inflammation and tissue damage. Primary 
mediators such as prostaglandins, serotonin, 
leukotrienes, and bradykinins reduce the threshold of 
high threshold nociceptive afferents and initiate the 
release of pain mediators such as substance P, CGRP 
and cholecystokinin in the site of injury, which leads 
to peripheral sensitization. Hence, weaker stimuli, 
which normally cannot produce pain, would now be 
perceived as painful. Histamine, nerve growth factor 
and norepinephrine are also involved in peripheral 
sensitization (5). There is also an increased number 
and proportion of tetrodotoxin-resistant channels in 
the affected neurons, which leads to the development 
of spontaneous ectopic activity (6). Reducing the 
inflammation would be the rational approach in 
controlling peripheral pain and use of NSAIDs, 
opioids and local anesthetics is advised. 
On the other level, central sensitization occurs 
as a result of long term potentiation of the central 
nerves, with NMDA and AMPA glutamate receptors 
and Wide Dynamic Range (WDR) neurons playing 
the vital role. WDR neurons receive signals from both 
innocuous and nociceptive sensory neurons from 
large areas of the body, but in the case of repeated 
nociceptive input, their threshold can decrease and 
their receptive field widen. This is due to NMDA 
receptor activation that ultimately leads to increased 
sensitivity of the WDR neurons. 
A delta and C fibers bring the Impulses from 
the peripheral nociceptors to synapse in the lamina II 
and lamina V; C fibers also synapse in the lamina I of 
the spinal cord before projecting cranially. In lamina 
V, neurotransmitters such as glutamate and aspartate, 
activate amino-3-hydroxyl- 5-methyl-4-proprionic 
acid (AMPA) and Kainate (KAR) receptors and 
transmit the pain signal with high speed. These 




 ion transfer but are 
nearly impermeable to Ca
2+
 ions.  
NMDA (N-methyl-D-aspartate) glutamate 
receptor is a membrane protein with an ion channel 




 into the cell 
and simultaneously transferring K
+
 to the outside of 




 ions can bind to 
specific sites on the receptor and block the flow of 
other cations through the open ion channel. Since 
these receptors are voltage gated, they need a positive 
change in the cell voltage which is brought upon by 
an AMPA-induced membrane depolarization, which 
displaces the magnesium or zinc from the channel 
passage and clears the way for the calcium ions to 
enter the neuron. Direct binding of the glutamate can 
further potentiate this process (5–7).  
The accumulation of calcium in cell brings it to 
a state of excitation without stimulation where spinal 
neurons are “wind up” and fired rapidly in a 
transcription independent manner.  
The transcription independent central 
sensitization processes such as wind up and early 
LTP, are heterosynaptic, and low threshold A Beta 
input evoke these responses after C fiber 
conditioning. This kind of central sensitization is 
reversible and with each repetitive stimulation the 
pain increases. In the transcription dependent central 
sensitization, prolonged noxious facilitation, leads to 
production of modified proteins as a result of 
activation of certain genes, therefore, Ca
2+
 influx and 
subsequently production of prostaglandins, nitric 
oxide, and superoxides increases. This process is 
believed to be mediated by inflammation and changes 
in the dorsal root ganglion, the dorsal horn, and 
irreversible structural modifications in the CNS (5). 
This process can ultimately lead to 
hyperalgesia as a result of central sensitization in 
spinal cord as well as higher regions of CNS such as 
anterior cingulate gyrus, amygdale, and rostroventral 
medulla (5). 
The neurokinin receptor (NK1) and 
cycloxygenase 2 (COX-2) are also involved in central 
sensitization; however they are not involved in 
hippocampal LTP. The phosphorylation of synaptic 
receptors and the insertion of AMPA receptors into 
the post-synaptic membrane is seen in both 
hippocampal early phase LTP and central 
sensitization, but in hippocampal LTP synaptic 
strengthening is the only mechanism, while other 
cellular mechanisms and neuronal network changes 
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are involved in central sensitization. These 
similarities should be noted when treating central 
sensitization to avoid the disturbance of memory 
formation and cortical function (8). 
Management of pain 
In order to effectively manage postoperative 
pain, appropriate measures should be implemented 
before, during and after the surgery.  
During the operation 
Preoperative management:  
In the preoperative setting, individual 
assessment of the patients, patient education, 
preemptive, and preventive analgesia are the main 
examples of such measures (2-3, 17). 
The analgesic plan, in respect to analgesic 
efficacy, potential side effects, and effects on 
recovery should be optimized depending on the 
surgical procedure. Evidence based recommendations 
for procedure specific pain management in the 
common adult surgeries has been developed by the 
prospect working group, which is a collaboration of 
surgeons and anesthesiologists, and it can be accessed 
freely on the website http://www.postoppain.org/. 
Intraoperative management 
Different neuroendocrine, metabolic, and 
inflammatory changes are involved in the stress 
response from the surgery, which can harm organs 
and ultimately increase postoperative pain. 
Hypothermia and psychological stress can increase 
these responses, while deeper levels of anesthesia, 
neural blockade, and reduced surgical invasiveness 
can diminish them. 
Intravenous Medications 
- Lidocaine: Lidocaine is the safest local anesthetic; 
it can reduce pain and inflammation when 
administrated as a 100mg IV bolus followed by an 
infusion of 2 to 3 mg/h in surgeries. Lidocaine has 
weak analgesic, but potent anti-hyperalgesic effect in 
humans; it decreases the need for opioids and helps 
with the early return of bowel function.  
- β-blockers: β-blockers can improve surgical stress 
response and inhibit sympathetic response to tracheal 
intubation. They also reduce the need for opioid and 
volatile anesthetic use (3). 
- α2 agonists: clonidine, tizanidine and 
dexmedetomidine are the most commonly used α2 
agonists in pain management. They can decrease 
opioid consumption due to their anesthetic and 
analgesic properties (9). Clonidine is administrated 
orally and can help with opioid withdrawal pains. 
Tizanidine acts more rapidly and is more beneficial in 
patients with spastic disorders. It also has less effects 
on blood pressure and heart rate (9). 
Dexmedetomidine is more selective, and it can be 
administrated IV. It works by hyperpolarization of 
neurons in locus ceruleus and therefore inhibiting the 
sympathetic-mediated pain at peripheral nociceptors 
which inhibits the release of pain mediators such as 
substance P and glutamate in primary afferent 
neurons, and the wind up effect in secondary neurons 
(9–11).  
- NMDA inhibitors: In a prospective, randomized, 
double-blinded study, a 0.5 mg/kg bolus of ketamine 
followed by continuous intravenous infusion of 0.25 
mg/kg/h during the surgery, decreased opioid 
consumption and reduced areas of hyperalgesia up to 
72 h after surgery, compared to placebo or epidural 
ketamine. IV Ketamine also decreased CPOP for up 
to 6 months after the surgery (11). Dextromethorphan 
also works with this mechanism and has shown to be 
effective in reducing postoperative pain and opioid 
consumption (effect of preoperative)  
Anesthesiology techniques: 
Different methods of administration can be 
used for anesthetic drugs to ensure the optimal 
analgesia and minimize side effects and use of 
opioids. The followings are the most commonly used 
methods used to decrease post-operative pain: 
-  Neuraxial techniques of analgesia, in which 
epidural or spinal administration of local anesthetic 
(with a low dose opioid) blocks the nociceptive 
stimuli and the stress response to surgery. 
Administration is performed before the surgery and 
can be continued after the surgery. This technique can 
also help with postoperative mobilization and reduce 
the risk of ileus. 
- Transversus Abdominus Plane Blocks, in which 
abdominal wall is anesthetized with peripheral nerve 
block for minor abdominal surgeries.  
- Peripheral Nerve Blocks, in which afferent 
nociceptive pathways are blocked. 
- Wound Infiltration Anesthesia, in which 
lidocaine or bupivacaine are infiltrated in the wound 
for local anesthesia. This method is fast acting and 
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epinephrine can be used to extend the duration of 
action. A liposomal formulation of bupivacaine has 
been developed to provide longer durations of action 
(up to 96 hours), but its clinical use is still limited due 
to insufficient comparative clinical data. 
- Tumescent Anesthesia, in which local anesthetic 
are diluted and administrated subcutaneously in large 
volumes with epinephrine and other agents.  
- Topical Local Anesthesia, in which special 
formulations of local anesthetics with the ability to 
penetrate the skin (lidocaine and prilocaine, lidocaine-
epinephrine-tetracaine and tetracainephenylephrine) 
are used on intact skin (before surgical incision) or 
cuts (to facilitate suturing in pediatric patients). 
Topical oxymetazoline or phenylephrine and 
lidocaine has also been used for mucosal analgesia (3, 
11).  
Postoperative Management 
Multimodal analgesia, is defined as the use of a 
combination of different analgesic medication and 
techniques, with different mechanisms of action in the 
peripheral and central nervous system to obtain 
additive or synergistic effects and increase the 
effectiveness of pain management (2). In this method 
individual personal and medical needs of patients are 
considered to obtain the best analgesia plan. Patients’ 
response and side effects are monitored afterwards 
and required alterations are made depending on 
patient’s needs. Physicians, anesthesiologists and 
nursing staff should all cooperate to maximize the 
success of pain management plan (12). Opioids are 
the key component in multimodal approach and other 
pharmacological and non-pharmacological 
interventions are added according to patient’s 
individual needs, to increase their efficacy from other 
mechanisms, and minimize their side effects. The 
interventions most commonly used in multimodal 
analgesia are as follows (3): 
- Non-pharmacologic therapies: Transcutaneous 
electrical nerve stimulation at incision site and 
cognitive modalities with guided imagery and other 
relaxation methods, hypnosis, intraoperative 
suggestions, and music. 
- Acetaminophen and NSAIDs, as oral or IV 
injections to reduce the use of postoperative opioids. 
A single dose of celecoxib before major surgeries, has 
shown to reduce post-operative pain and opioid 
consumption (2). 
- Opioids in IV, IM, oral, transdermal, rectal, 
sublingual, subcutaneous, neuroaxial administration 
routes, morphine, hydromorphone, fentanyl and 
tramadol are used more frequently. In patients with 
severe pain who need more frequent injections, 
patient controlled IV analgesia with opioids is used 
(3). 
- Gabapentin and pregabalin which can be 
administrated before or after the surgery (PIIS). 
- Corticosteroids (13), dexamethasone (8 mg IV) is 
the best option, since it can help with nausea and 
vomiting after the surgery. 
Experimental drugs and pain control methods 
With the increase in the rate of surgical 
operations, postoperative pain is gaining more 
attention in scientific studies, with the aim of finding 
more effective drugs and procedures with less side 
effects. 
Since various complex mechanisms are 
involved in the spinal pain amplification caused by 
surgical insult, numerous therapeutic targets can 
interfere with this process. Therapies may target 
neuronal or non-neuronal processes of sensitization. 
Sensitization is also dependent on calcium influx and 
inflammation processes. Some therapeutics modulates 
neuronal activity or by blocking receptor proteins 
such as NMDA and AMPA receptor, which increase 
intracellular calcium levels during neuronal 
activation. Other therapies may target CNS 
inflammation (11). An overview of the main 
experimental approaches for management of 
postoperative pain is presented here.  
Acupuncture: auricular acupuncture, in which 
needles are placed in various parts of the earlobe has 
been shown to be beneficial in post-operative pain 
control, but larger studies with improved quality are 
needed to obtain a definitive conclusion in this matter 
and justify the routine use of this method (5). 
Probiotics: Probiotics has shown beneficial 
effects on inflammatory pain, by inhibiting pro-
inflammatory mediators and increasing the production 
of anti-inflammatory cytokines in animal models. The 
adjuvant use of probiotics should be considered in the 
postoperative period, due to their nonexistent side 
effects (14).  
Magnesium: Administration of IV magnesium 
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after major GI surgery has shown to reduce 
postoperative ileus, postoperative severe pain and 
perioperative analgesic requirements in a randomized 
clinical trial. Magnesium has no side effects in these 
doses and its routine administration can be advised for 
major GI surgeries (15). 
Pulsed electromagnetic fields: PEMF 
improves calmodulin-dependent nitric oxide and/or 
cyclic guanosine monophosphate signaling, but it can 
also increase phosphodiesterase activity which 
inhibits cyclic guanosine monophosphate activity. At 
certain intervals, this method has demonstrated 
beneficial effects in postoperative pain in breast 
reduction patients (16).  
Glutamate receptor antagonism: as 
mentioned before, glutamate plays a key role in 
central sensitization and pain, and different 
glutamatergic receptors and pathways have been 
investigated for their potential in treatment of 
neuropathic and postoperative pain. Currently 
ketamine, dextromethorphan, amantadine, and 
memantine, are clinically available as NMDA 
receptor antagonists (17). Other drugs such as MK-
801 (i.e. dizocilpine), AP5, traxoprodil and 
norketamine, works with the same mechanism and 
has been introduced in the literature as treatments for 
postoperative pain (11). Other than inhibition of the 
NMDA receptor itself, other molecules involved in 
the phosphorylation of these receptors can also be 
considered as therapeutic targets. Examples of such 
molecules are protein kinase A (PKA) which has a 
role in phosphorylation of NR1 subunit and the Src. 
family of protein which are involved in NR2B 
phosphorylation (11). Although IV administration of 
ketamine is associated with side effects such as 
hallucination, combined use of these agents with 
opioids, while reducing the need for opioids, does not 
bare any additional side effects when compare to 
opioids alone (17). AMPA receptors (18) and G 
protein-coupled metabotropic glutamatenreceptors, 
mGluR 1 and 5, are other interesting targets in these 
pathways and several substances has been introduced 
as antagonists for this receptors (19), but although 
animal studies were promising, more clinical studies 
are needed to find the best molecule for human use. 
Opioids- New substances and new administrations 
 Tapentadol is a novel opioid analgesic with 
potency between tramadol and morphine but with less 
abuse potential than all other opioid analgesic drugs. 
It has a unique ability to inhibit norepinephrine 
reuptake as well as its agonistic effect on µ receptors. 
Incidence of nausea and vomiting is also lower with 
this drug compared to oxycodone (5,20,21). It can be 
used both in preemptive treatment and postoperative 
period to manage the pain (22). Since the risk for 
addiction is one of the most important challenges 
when using opioids, there’s an increasing interest 
focused on development of abuse-deterrent 
formulations of opioids. Such formulations are based 
on technologies such as physical or mechanical 
barriers or the addition of a noxious component (e.g. 
niacin) or an antagonist (e.g. naloxone, naltrexone) 
(23). A typical example is slow-release oxycodone 
formulation that combines a mechanical and a 
physical barrier effect which prevents crushing or 
drawing out drug for injection (23).  Although these 
preparations require further evaluation, it has been 
suggested that they may well become the standard of 
care in the future (24). 
Capsaicin: (8-methyl-N-vanillyl-6-
nonenamide) is a TRPV-1 (transient receptor potential 
vanilloid 1) agonist which can be found in chili 
pepper seeds, it is non-narcotic and acts peripherally 
(24). TRPV1 receptors are present on unmyelinated C 
fiber endings in the periphery, and they tend to be 
significantly reduced in inflammatory conditions. The 
activation of the TRPV receptors produces high 
intensity impulses which lead to the release of 
substance P, and a burning sensation. C fiber 
activation is ultimately reduced when substance P is 
depleted. The A delta and A alpha fibers are not 
significantly affected by capsaicin. It is available in 
injection and topical forms. It is thought to have 
opioid sparing effects and can be used as an adjuvant 
in a variety of pain disorders, especially in age groups 
more sensitive to opioid adverse effects. The initial 
burning sensation with this molecule can be managed 
with pre-administration of neural blockade before 
injection of capsaicin. Capsaicin’s favorable safety 
profile makes it an interesting choice in the 
management of postoperative pain and there are more 
attempts to identify therapeutically useful agonists 
and antagonists for the TRPV1 receptor (25, 26). 
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Immune modulation with glial modulators  
According to recent findings astrocytes and 
microglia, central and peripheral, participate in 
neuronal hyper excitability and chronic pain (27). 
These resulted in an increased focus on these cells as 
targets in pain management. However, although 
animal studies demonstrate an overall beneficial 
effect from glial modulators in treatment of pain and 
central sensitization, and brain glial activation in 
chronic pain patients has been established, human 
studies have so far yielded diverse results (28). An 
example of these modulators is propentofylline, 
which proved to be beneficial in a variety of rodent 
pain models in reducing pain hypersensitivity but 
failed to indicate a beneficial effect in postherpetic 
neuralgia, in a Phase IIa clinical trial. It seems that 
different aspects of pain and differences between 
humans and animal models should be determined 
carefully to ensure successful translation of use of glia 
modulators in human (29). 
Immune modulation with anti-cytokines agents 
Cytokines have also been directly targeted in 
order to modulate inflammatory processes in pain 
(30). Intrathecal etanercept as a TNF inhibitor was 
found effective in preventing phosphorylation of the 
AMPA-subunit GluR1 in the spinal dorsal horn, and 
also SNL pain models, with optimal effect achieved 
when the drug was administrated early after nerve 
injury (11). Intrathecal IL-1ra was not found 
beneficial in the SNT model of peripheral nerve 
injury, but it was found effective in attenuating 
established mechanical hypersensitivity at 7 days after 
induction of CCI of the sciatic nerve and reversing 
mechanical pain hypersensitivity at 96 h after 
intraplantar CFA injection (31). Interference with IL-
1b signaling was also effective in reducing 
established inflammatory pain. As a biological 
inhibitor of TNF-a signaling, intraperitoneal injection 
of Erythropoietin (EPO) and the synthetic peptide 
ARA290 which mimicks its effects, has demonstrated 
beneficial effects in SNT nerve injury with reduced 
SNT-induced inflammation and attenuation of SNT-
induced increases in the levels of GFAP, TNF-a, and 
IL-1b (32). Although these data are highly 
impressive, the clinical use of these drugs and their 
risk benefit profile are yet to be determined in larger 
scale clinical trials. 
Antidepressants : Although the efficacy of 
antidepressants in acute postsurgical pain has been 
suggested in numerous clinical trials, most of these 
trials are old and their results are limited by not 
specifying primary outcomes, disregarding 
movement-evoked pain, small size and insufficient 
safety assessment (33,34). Data on use of 
antidepressants in prevention of chronic postsurgical 
pain is inclusive with only one of three trials in this 
indication suggesting any efficacy. Therefore, current 
evidence does not yet support routine use of any one 
specific antidepressant for treatment of acute, or 
prevention of chronic, postsurgical pain and further 
larger trials are needed to determine optimal dosing 
and duration of antidepressant treatment, procedure 
specificity, safety profile, and assessment of 
movement-evoked pain (35). 
Cannabinoids are a group of proteins 
including endocannabinoids such as anandamide 
(produced naturally in the body by humans and 
animal), the phytocannabinoids (found in cannabis 
and some other plants), and synthetic cannabinoids 
(manufactured chemically) which act on cannabinoid 
receptors (36). Since cannabinoid receptors are 
thought to be involved in analgesic, euphoric and 
anticonvulsive processes (CB1) and also demonstrate 
anti-inflammatory and immunosuppressive effects 
(CB2), cannabinoids represent an interesting target 
for neuropathic pain management. However the 
overall clinical data available is still limited and 
confusing, and suggests limited efficacy from drugs 
on this category in some neurologic disorders, such as 
chronic neuropathic pain conditions, in MS and AIDS 
(24). 
Resolvins: A large number of evidence 
supports the potent anti-inflammatory and pro-
resolution actions of omega-3 polyunsaturated fatty 
acids-derived lipid mediators, such as resolvins, 
lipoxins, and neuroprotectins in various animal 
models of inflammation (37). Resolvin E1 (RvE1) is 
an eicosapentaenoic acid (EPA) derivative that with 
peripheral spinal, or systemic administration at very 
low doses, has shown to reduce inflammatory pain, 
via transient receptor potential ion channel (TRPV1) 
and modulating microglial signalin (38). Mechanism 
of RvE1 activates the G-protein-coupled receptor 
ChemR23, widely expressed in immune cells 
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(macrophages), neurons (primary sensory neurons and 
spinal cord neurons), and microglia (39).  
Calcitonin: Calcitonin is a polypeptide 
hormone produced naturally in humans by the 
parafollicular cells of the thyroid gland (40). It is 
commonly used in treatment of osteoporosis and 
Paget’s disease. Calcitonin’s use in acute and chronic 
pain states has been examined in different studies. A 
more recent network meta-analysis supports short-
term use of calcitonin in later stages of complex 
regional pain syndrome (24). There is also limited 
evidence that calcitonin can be used in acute, but not 
chronic, phantom limb pain after amputation (41). 
Vitamin C: Several trials have been conducted 
on use of vitamin C in postoperative pain. A meta-
analysis of the available references in 2016 concluded 
that there is moderate-level evidence supporting that 
preoperative dose of 2 g vitamin C can be used as an 
adjunct for its opioid spring abilities, and high-level 
evidence is available that supplementation of 1 g/d 
vitamin C for 50 days is useful in prevention of 
complex regional pain syndrome type I after 
extremity surgery (42). Additional studies can be 
useful in determining overall effectiveness and 
optimum dosage of vitamin C. 
Conclusion 
Postoperative pain is a complex 
phenomenon which depends on several factors, 
from type of the surgery and the skill of the 
surgeon to patient’s characteristics and 
background history. Effective management of 
postoperative pain requires identification of 
these factors and their underlying molecular 
mechanisms, and planning an individual 
approach for each patient accordingly using 
multimodal analgesia. Pain prevention should 
be considered in all stages of surgery, 
preoperative and postoperative period, and 
each member of the medical team should play 
their parts optimally to minimize patient’s 
harm and improve surgical outcomes. 
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